Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 86 recruiting now later-stage tilt #19 of 28,707 conditions

Diabetes: later-stage trial registry

86 of 342 indexed Diabetes trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #19 of 28,707 conditions by registered trial count.

342 US clinical trials · 86 currently recruiting · #19 of 28,707 conditions by registered trial count

Diabetes: 342 US clinical trials tracked, 86 recruiting.

Diabetes is the subject of 342 registered US clinical trials on ClinicalTrials.gov, 86 of them currently open to new participants. 55 are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 41 of these trials.

Enrollment posture brief

Registry condition diabetes

OPEN 86 | RECR 25% | LATE 55 | EARLY 36 | RANK #19 | SPON 41

Nearest open-share peer: Low Back Pain (25% recruiting · 123 trials)

Ovarian Cancer43.5%Type 2 Diabetes36.6%Lymphoma26.7%Diabetes (this)25%Diabetes Mellitus, Type 217.9%
Open-enrollment share among volume-matched conditions near Diabetes

Diabetes lists 86 open slots (25% of 342 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetes is recruiting below its size-band peers.

    86 of 342 indexed trials (25.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Diabetes trials is spread across many organizations.

    Novo Nordisk A/S accounts for 41 of 342 trials (12%). 161 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetes enrolment sits around 150 participants.

    Median target enrolment is 150 among the 339 trials that report a genuine target (sentinel values excluded). 144 of those (42.5%) plan for fewer than 100 participants.

  4. Diabetes research is mostly interventional.

    263 interventional and 79 observational studies make up this index (76.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 123Phase 213Phase 337Phase 418

Open and recent trials

342 total, page 7 of 7

COMPLETED NA 30 participants

Nonvisual Foot Inspection for People With Visual Impairment

Case Western Reserve University

NCT01822717

COMPLETED NA 30 participants

High-risk Obstetrical Patient Intervention Utilizing the Contraceptive CHOICE Project Script

University of California, San Diego

NCT03049592

COMPLETED Phase 4 30 participants

Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

Veterans Medical Research Foundation

NCT00895921

COMPLETED 30 participants

Periodontal and Periapical Inflammation and Pregnancy

Roger Johnson

NCT00490165

COMPLETED NA 30 participants

Translating the Diabetes Prevention Program Into a Virtual Lifestyle Management Program

University of Pittsburgh

NCT00867425

COMPLETED Phase 1 28 participants

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

Wockhardt

NCT00752180

COMPLETED Phase 3 27 participants

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

Novo Nordisk A/S

NCT00065130

COMPLETED Phase 2 26 participants

A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain

TheraVasc

NCT02412852

COMPLETED NA 26 participants

N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes

City of Hope Medical Center

NCT02065310

COMPLETED NA 25 participants

Diabetes Education and Care for Deaf Populations

University of Utah

NCT06577506

COMPLETED NA 23 participants

Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension

InVasc Therapeutics

NCT00795262

COMPLETED 23 participants

Assessment of Stability of Mail-in Capillary Hemoglobin A1c Test Kit

Children's Mercy Hospital Kansas City

NCT00511030

COMPLETED NA 23 participants

Pathways Linking Reduced Sleep Duration and Quality to Obesity Risk

University of Chicago

NCT00915707

COMPLETED NA 22 participants

Free Test Strips and Blood Glucose Control

University of Wisconsin, Madison

NCT00205335

COMPLETED Phase 1 21 participants

Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery

The Cleveland Clinic

NCT00488423

COMPLETED Phase 1 20 participants

Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption

NatureGen

NCT00262145

COMPLETED Phase 4 20 participants

Depression-Diabetes Mechanisms: Urban African Americans

Emory University

NCT00209170

COMPLETED Phase 1 20 participants

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Novo Nordisk A/S

NCT01511185

COMPLETED NA 20 participants

Non-invasive Measurement of Microvascular Blood Flow During Mild External Compression of the Leg

University of California, San Diego

NCT01804478

COMPLETED NA 20 participants

Adjusting Insulin Delivery to Activity

Boston Children's Hospital

NCT02299479

COMPLETED Phase 1 19 participants

Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NCT01419535

COMPLETED NA 17 participants

Insulin Secretion in Diabetes Before and After Glycemic Control

US Department of Veterans Affairs

NCT00469833

COMPLETED NA 16 participants

Mitochondrial Dysfunction in Diabetes

Mayo Clinic

NCT01724502

COMPLETED Phase 1 16 participants

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

Hartford Hospital

NCT02620774

COMPLETED NA 16 participants

Barley Beta-glucan, Glycemic Control, and Appetite

Washington State University

NCT06146322

COMPLETED NA 15 participants

Glucose Measurement Using Microneedle Patches

Emory University

NCT02682056

COMPLETED Phase 1 15 participants

Fructose-Induced Palmitate Synthesis in Overweight Subjects

Rockefeller University

NCT00535535

COMPLETED 14 participants

Evaluation of a Non-invasive Brain Compliance Measurement Device

Stanford University

NCT01753921

COMPLETED NA 12 participants

HOPE Pilot for Veterans With Complex Diabetes

Michael E. DeBakey VA Medical Center

NCT01274715

COMPLETED NA 12 participants

A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling

The University of Texas Health Science Center at San Antonio

NCT01740817

COMPLETED NA 12 participants

FFA Hypertension and Inflammation in Lean and Obese Subjects

Emory University

NCT00721617

COMPLETED 12 participants

Microbial Determinants of Dementia Risk in Type 2 Diabetics of Mexican Descent

The University of Texas Medical Branch, Galveston

NCT04602650

COMPLETED 10 participants

Implementation of a Cardiometabolic Disease Staging System in Primary Care

University of Alabama at Birmingham

NCT04922294

COMPLETED NA 10 participants

Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes

Children's Hospital of Philadelphia

NCT03303196

COMPLETED NA 10 participants

Intestinal Sweet Taste Receptor Function and Adaptation to Dietary Sugars and Sweeteners

AdventHealth Translational Research Institute

NCT02835859

COMPLETED 10 participants

A Study to Evaluate Glucose and Insulin Response to Nutralin

Avera McKennan Hospital & University Health Center

NCT01275820

COMPLETED NA 6 participants

The Mobile Health Platform

Duke University

NCT02099513

COMPLETED Phase 1 6 participants

RBC Lifespan Measurement in Diabetic Children

Guohua An

NCT03073070

COMPLETED NA 4 participants

Novel Therapies for Metabolic Complications of Lipodystrophies

University of Texas Southwestern Medical Center

NCT00457938

COMPLETED Phase 2 3 participants

Effects of Human Leptin Replacement

University of Miami

NCT00657605

COMPLETED

Examining Macrophage Influx and Vascularization in Chronic Pancreatitis

University of Colorado, Denver

NCT00491023

COMPLETED

Epidemiology of Hearing Loss in Diabetic and Non-Diabetic Veterans

US Department of Veterans Affairs

NCT00018486

← Previous Page 7 of 7

Phase Distribution

PhaseTrial count
Phase 1 23
Phase 2 13
Phase 3 37
Phase 4 18

Named interventions

Most-linked intervention names on Diabetes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

insulin degludec Drug
11 trials
Placebo Drug
10 trials
insulin glargine Drug
9 trials
insulin aspart Drug
9 trials
semaglutide Drug
7 trials
liraglutide Drug
6 trials
placebo Drug
6 trials
insulin detemir Drug
4 trials

US sites by state

Facility locations filed on Diabetes trials. A trial with sites in several states counts in each.

California 82 trials
Florida 59 trials
Maryland 39 trials
Georgia 38 trials
Massachusetts 35 trials
Texas 33 trials
New York 31 trials
Colorado 31 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetes page

342 registered trials, 86 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes condition card totals 342 registered trials; most-linked intervention insulin degludec; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.